

N-Nitroso-N-ethylurea

Division of Safety National Institutes of Health



WARNING!

THIS COMPOUND IS TOXIC, CARCINOGENIC, MUTAGENIC, AND TERATOGENIC. ALKALINE HYDROLYSIS PRODUCES DIAZOETHANE, WHICH IS A HIGHLY TOXIC, IRRITATING, CARCINOGENIC, HIGHLY FLAMMABLE, AND EXPLOSIVE GAS.

LABORATORY OPERATIONS SHOULD BE CONDUCTED IN A FUME HOOD, GLOVE BOX, OR VENTILATED CABINET.

AVOID SKIN CONTACT: IF EXPOSED, WASH WITH SOAP AND COLD WATER. AVOID RUBBING OF SKIN OR INCREASING ITS TEMPERATURE.

FOR EYE EXPOSURE, IRRIGATE IMMEDIATELY WITH LARGE AMOUNTS OF WATER. FOR INGESTION, DRINK MILK. REFER FOR GASTRIC LAVAGE. FOR INHALATION, REMOVE VICTIM PROMPTLY TO CLEAN AIR. ADMINISTER RESCUE BREATHING IF NECESSARY. REFER TO PHYSICIAN.

IN CASE OF LABORATORY SPILL, WEAR PROTECTIVE CLOTHING DURING CLEANUP. WASH DOWN AREA WITH SOAP AND WATER. DISPOSE OF WASTE SOLUTIONS AND MATERIALS APPROPRIATELY.

A. Background

N-Nitroso-N-ethylurea (ENU) is toxic, carcinogenic, mutagenic, and teratogenic in animals and experimental test systems. Its primary use is for tumor induction and related research in experimental animals and as a research mutagen.

B. Chemical and Physical Data

1. Chemical Abstract No.: 759-73-9

issued 3/82

```
ENU
                                      1-Ethyl-1-nitrosourea
  NEU
                                      N-Nitrosoethylurea
  Ethylnitrosourea
                                      Nitrosoethylurea
  N-Ethyl-N-nitrosourea (9CI)
Molecular
  formula:
                      structure:
    C3H7N3O2
  weight:
    117.1
Density: No data.
Absorption spectroscopy: IR, UV, NMR spectra have been reported
by Heyns and Roper (1974). UV (CH<sub>2</sub>Cl<sub>2</sub>): \lambda (log \epsilon) = 237 (3.85), 401 (2.08), and 418 (2.04) (Mirvish, 1971).
Volatility: No data. May be nonvolatile by analogy with N-nitroso
N-methylurea (Mirvish et al., 1976).
Solubility: Approximately 1.3% in water at room temperature.
Soluble in polar organic solvents.
Description, appearance: Yellow to pink crystals.
Boiling point: No data.
Melting point: 102-104°C (with decomposition).
Stability: The pure compound is sensitive to humidity and light
and should be stored in the dark at less than -10°C in tightly
closed containers protected from moisture. Stability in aqueous
solution is pH dependent, with maximum stability occurring at about
pH 4 (Druckrey et al., 1967).
Chemical reactivity: ENU is an alkylating agent. It is hydrolyzed
by strong alkali (liberating diazoethane, a highly toxic gas) and
by strong acid.,
Flash point: Does not apply.
Autoignition temperature: No data.
Flammable limits:
                    Does not apply.
```

Synonyms:

e, Explosion, and Reactivity Hazard Data Dry chemical or carbon dioxide extinguishers may be used.

masks. Decomposition products may be explosive. Sealed bottles at room temperature may explode due to gas pressure.

Fire fighters should wear air-supplied respirators with full-face

irritating, flammable, and explosive gas.

rational Procedures

cribe operational practices to be followed when potentially cinogenic chemicals are used in NIH laboratories. The Guidelines

be washed with water.

cultures) containing ENU shall be disinfected by heat using a

standard autoclave treatment and packaged for incineration, as

above. Burnable waste (e.g., absorbent bench top liners) minimally

contaminated with ENU shall be handled as potentially infectious waste and packaged for incineration, as above. Absorbent materials (e.g., associated with spill cleanup) grossly contaminated shall be handled in accordance with the chemical waste disposal system.

of water. Glassware should be rinsed (in a hood) with a polar organic solvent, followed by soap and water. Animal cages should Disposal: No waste streams containing ENU shall be disposed of in sinks or general refuse. Surplus ENU or chemical waste streams contaminated with ENU shall be handled as hazardous chemical waste and disposed of in accordance with the NIH chemical waste disposal system. Nonchemical waste (e.g., animal carcasses and bedding) containing ENU shall be handled and packaged for incineration in accordance with the NIH medical-pathological waste

disposal system. Potentially infectious waste (e.g., tissue

spilled or if there is any uncertainty regarding the procedures to be followed for decontamination, call the NIH Fire Department (dial 116) for assistance. Wash surfaces with copious quantities

Decontamination: Turn off equipment that could be affected by ENU or the materials used for cleanup. If more than 1 g has been

uld be consulted to identify the proper use conditions required specific controls to be implemented during normal and complex rations or manipulations involving ENU. Chemical inactivation: No validated method reported.

NIH Guidelines for the Laboratory Use of Chemical Carcinogens

Alkaline hydrolysis produces diazoethane, which is a highly toxic, Avoid contact with alkaline solutions.

Incompatible with water.

Sensitive to light and moisture.

- Radioactive waste containing ENU shall be handled in accordance with the NIH radioactive waste disposal system.
- 4. Storage: Store working quantities of ENU and its solutions in a safety refrigerator in the work area. Store stocks of ENU below -10°C in amber bottles with caps and Teflon cap liners. Do not store in ampoules since these could explode. Avoid exposure to light and moisture.

Monitoring and Measurement Procedures Including Direct Field Measurements and Sampling for Subsequent Laboratory Analysis

- Sampling: ENU could be found in aerosols formed in the laboratory, but no reliable sampling method for this potential hazard has been reported.
- Separation and analysis: HPLC and TLC are appropriate for separation of nitrosamides. UV spectrophotometric detection has been used with HPLC (Heyns and Roper, 1974) and TLC (Mirvish and Chu, 1972) for detection and quantitative determination of nitrosoureas.

ENU is also readily determined colorimetrically as nitrite after

acidic hydrolysis (Preussmann and Schaper-Druckrey, 1972).

Biological Effects (Animal and Human)

1.

absorbed through the skin in analogy with findings with N-nitroso-N-methylurea.

2. Distribution: Intravenous administration of ¹⁴C-ENU to pregnant

Absorption: ENU is absorbed and produces toxic effects after

ingestion and parenteral administration. It is also likely to be

- rats results in distribution of the radiolabel to both maternal and fetal brain and liver in the form of ethylated guanine residues.
- 3. Metabolism and excretion: The high chemical reactivity of ENU makes it unlikely that an enzymatic metabolism is involved to any significant extent in the activation of ENU. The breakdown of ENU in vivo generates a short-acting carcinogenic intermediate that yields an ethylcarbonium ion that ethylates proteins and nucleic
- acids. No excretion products have been identified (IARC, 1978).

 4. Toxic effects: Acute LD50s for the rat are 240, 240, and 300 mg/kg by the intravenous, subcutaneous, and oral routes, respectively. Target organs in the offspring of pregnant mice are brain (demyelination) and eyes. Bone marrow degeneration occurs in mice after intraperitoneal injection of ENU.
- 5. Carcinogenic effects: ENU is carcinogenic in all animal species tested. Principal target organs are the central and peripheral nervous system in young rats on oral or subcutaneous administration and the hematopoietic system (resulting in leukemias) on intravenous injection. Older rats also show a high tumor incidence of kidney, uterus, and ovary. In the mouse, the chief target organ is the lung. ENU is especially effective as a transplacental carcinogen.

6. Mutagenic and teratogenic effects: ENU is mutagenic in human lymphocyte and fibroblast cultures and in algae. Teratogenic effects have been noted transplacentally in rats, mice, pigs, and hamsters.

Emergency Treatment

- 1. Skin and eye exposure: For skin exposure, remove contaminated clothing and wash skin with soap and water. Avoid rubbing of skin or increasing its temperature. For eye exposure, irrigate immediately with copious quantities of running water for at least 15 minutes.
- 2. Ingestion: Vomiting might reexpose the mouth and esophagus. Drink milk; it may react with nitrosamides. Refer for gastric lavage.
- Inhalation: Remove victim promptly to clean air. Administer rescue breathing if necessary.
- 4. Refer to physician.

References

- Druckrey, H., R. Preussmann, S. Ivankovic, and D. Schmähl. 1967. Organotropic carcinogenic action of 65 different N-nitroso compounds with BD rats. Z Krebsforschung 69:193-201.
- Heyns, K., and H. Roper. 1974. Analysis of N-nitroso compounds. Part 2. Sampling and quantitative determination of homologous N-nitroso-N-alkylureas and N-nitroso-N-alkylurethans by rapid high pressure liquid chromatography. J Chromatogr 93:429-439.
- IARC. 1978. IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Humans, Some N-Nitroso Compounds, Vol. 17. World Health Organization, Geneva, Switzerland.
- Mirvish, S.S. 1971. Kinetics of nitrosamide formation from alkylureas, N-alkylurethans, and alkylguanidines: Possible implications for the etiology of human gastric cancer. J Natl Cancer Inst 46:1183-1193.
- Mirvish, S.S., and C. Chu. 1972. Chemical determination of methyl and ethyl nitrosourea in rat stomach contents after intubation of the alkylureas plus sodium nitrite. J Natl Cancer Inst 50:745-750.
- alkylureas plus sodium nitrite. J Natl Cancer Inst 50:745-750. Mirvish, S.S., P. Issenberg, and H.C. Sornson. 1976. Air-water and ether-water distribution of N-nitroso compounds: Implications for laboratory safety, analytic methodology, and carcinogenicity for the rat esophagus, nose, and liver. J Natl Cancer Inst 56(6):1125-1129.
- Preussmann, R., and E. Schaper-Druckrey. 1972. Investigation of a colorimetric procedure for determination of nitrosamides and comparison with other methods. Page 81 in P. Bogovski, R. Preussmann, and E.A. Walker, eds. N-Nitroso Compounds Analysis and Formation: Proceedings of a Working Conference Held at the Deutsches Krebforschungszentrum, Heidelberg, Federal Republic of Germany, 13-15 October, 1971. IARC Scientific Publications No. 3. World Health Organization, Geneva, Switzerland.